Positive New Clinical Data Demonstrating High Rates of Durable CRs from the Ph 1/2 Trial of LYL314 in Aggressive Large B-cell Lymphoma Announced June 24, 2025
Lunsumio and Polivy Combination Significantly Prolongs Remission for People With R/R Large B-Cell Lymphoma June 24, 2025
FDA Approves Monjuvi (tafasitamab-cxix), Rituximab, and Lenalidomide Combination for Patients with R/R Follicular Lymphoma June 24, 2025
Enterome raises $19 million to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma June 17, 2025
FDA Breakthrough Therapy Designation granted to Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) June 10, 2025
EC Approves ADCETRIS® (brentuximab vedotin) for the Treatment of 1L Patients with Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD June 10, 2025
FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab + Chemo for Patients With R/R DLBCL May 27, 2025
NMPA approves Minjuvi (Tafasitamab) + Lenalidomide for the treatment of Adult Patients with R/R DLBCL in China May 27, 2025
Nearly 50 Sites Activated Across U.S. for Pivotal Ph 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation in LBCL May 21, 2025
Updated Ph 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of NHL Announced May 21, 2025
CR achieved after 1 month of the in vivo CD19 CAR-T treatment, with durable response sustained over three months in R/R DLBCL patients May 6, 2025
Supplemental BLA submission to FDA for Epcoritamab + Rituximab and Lenalidomide (R2) in Patients with R/R Follicular Lymphoma planned May 6, 2025
EMA gives IMPD approval to initiate Ph 1 trial of OT-C001 + Rituximab in DLBCL patients April 30, 2025
Ph 1/2a CARMA study of ELC-301 continues as planned following the safety committee’s assessment of cohort 1 April 22, 2025
